Solid Tumor
Conditions
Keywords
HMPL-453, FGFR, PD-1,IHCC, ICC, gastric cancer
Brief summary
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination with Chemotherapy or Toripalimab in Advanced Solid Tumors
Detailed description
The study includes a dose escalation phase and a dose-expansion phase. Patients with advanced solid tumor will be enrolled in the dose escalation phase to assess the tolerability, safety, and PK profile of HMPL-453 monotherapy or combination therapy. Patients with specific types of advanced or metastatic tumors harboring certain FGFR gene alterations will be enrolled in the dose expansion phase to assess the preliminary efficacy of HMPL-453 monotherapy or combination therapy.
Interventions
DRUGHMPL-453
HMPL-453 administered orally.
DRUGgemcitabine and cisplatin
Gemcitabine and Cisplatin administered intravenously.
DRUGtoripalimab
Toripalimab administered intravenously.
DRUGDocetaxel
Docetaxel administered intravenously.
Sponsors
Hutchison Medipharma Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Dose escalation phase: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumor who progressed on or are intolerant of standard therapy; * Dose expansion phase: patients with UC, GC/GEJ, or IHCC harboring specific FGFR gene alterations; * Age 18 to 75 years; * Those who are able to give written informed consent, and able to comply with protocol-specified visits and related procedures; * Ability to swallow study drug; * ECOG PS of 0 or 1; * Measurable lesion according to RECIST v1.1, refer to the protocol; * Adequate organ and bone marrow function; * Life expectancy ≥ 12 weeks; * Female patients or male patients with partners of childbearing potential must take effective contraceptive measures per the protocol.
Exclusion criteria
* Patients who previously received selective FGFR targeting therapy; * Concurrent participation in another interventional clinical study, excluding those in the follow-up period and have not recently received investigational intervention; * Current or previous history of central nervous system (CNS) metastases； * Current or previous history of retinal detachment； * Known history of primary immunodeficiency; * Female patients who are pregnant or lactating； * Patients who in the opinion of the investigator may be unsuitable for participating in the study; * Patients with acute or chronic active hepatitis B or C infection; * Known human immunodeficiency virus (HIV) infection and syphilis infection； * Clinically significant cardiovascular disease such as congestive heart failure or arrhythmia； * Uncontrolled hypertension despite optimal medical management； * Received live vaccine within 30 days before the first dose of study drug(s); * Those who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first study treatment or who are expected to be in need of major surgery; those with unhealed wounds, ulcers or fractures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability(Incidence and severity of adverse events (AEs)) | 6 months after the last patient enrolled | DLT, TEAEs and SAEs |
| Preliminary efficacy/Objective response rate (ORR) | up to 2 years | Objective response rate (ORR) in patients with the selected tumors along with certain FGFR gene alterations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy/Progression-free survival (PFS) | up to 2 years | the duration between the enrollment date and the first disease progression (PD) or death (whichever comes first). |
| disease control rate (DCR) | up to 2 years | The incidence of complete response, partial response and stable disease |
| time to response (TTR) | up to 2 years | The period from the date of enrollment to the date when the criteria for complete response or partial response was first measured (first record shall prevail). |
| duration of response (DoR） | up to 2 years | The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded |
| overall survival (OS) | up to 2 years | The period from date of enrollment to date of death |
Countries
China
Outcome results
None listed